Next Article in Journal
Pathophysiological Integration of Metabolic Reprogramming in Breast Cancer
Next Article in Special Issue
Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
Previous Article in Journal
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
Previous Article in Special Issue
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681

1
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2SY, UK
2
Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2SY, UK
*
Authors to whom correspondence should be addressed.
Submission received: 13 December 2021 / Accepted: 16 December 2021 / Published: 10 January 2022
(This article belongs to the Special Issue Therapeutic Targets in Chronic Lymphocytic Leukemia)
The authors wish to make the following corrections to their paper [1]:
  • There was an error in the original publication. Page 3. “Monoallelic TP53 aberrations exert a more detrimental prognostic impact, compared to biallelic alterations.” This is incorrect. It should read: “Monoallelic TP53 alterations exert a less detrimental prognostic impact, compared to biallelic alterations.”
  • There was an error in the original publication. Page 13. “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [2].” Reference [2] was erroneously cited. The correct reference here should be reference [1]. This sentence should read: “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [1].”
  • There was an error in the original publication. Page 14. “in combination with existing immunomodulatory agents such as the PD-1/PD-L1 inhibitors lenalidomide and ibrutinib” This sentence should read in “in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib.”
  • In the original publication, there was a mistake in Table 1: “Döhner” was misspelt as “Doner”. The corrected Table 1 appears below.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

Reference

  1. Kwok, M.; Agathanggelou, A.; Davies, N.; Stankovic, T. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. [Google Scholar] [CrossRef]
Table 1. Frequency of different p53 pathway alterations in patients with chronic lymphocytic leukemia.
Table 1. Frequency of different p53 pathway alterations in patients with chronic lymphocytic leukemia.
GeneMutation
Frequency
Deletion
Frequency
Number of Patients AnalyzedReference
ATMND18%325Döhner et al., 2000 [17]
32%4%50Stankovic et al., 2002 [13]
12%3%155Austen et al., 2005 [14]
ND22%330Malcikova et al., 2009 [15]
14.7%30%224Skowronska et al., 2012 [19]
8%15%160Landau et al., 2013 [25]
15%22%538Landau et al., 2015 [26]
TP53ND7%325Döhner et al., 2000 [17]
12%6%50Stankovic et al., 2002 [13]
4%ND155Austen et al., 2005 [14]
5%11%400Malcikova et al., 2009 [15]
8.5%5%328Zenz et al., 2010 [16]
7.6%6%529Gonzalez et al., 2011 [27]
15%ND309Rossi et al., 2014 [28]
11.5%7%635Stilgenbauer et al., 2014 [29]
13%13%160Landau et al., 2013 [25]
7%6.3%538Landau et al., 2015 [26]
Abbreviations: ND, not determined.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kwok, M.; Agathanggelou, A.; Davies, N.; Stankovic, T. Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. Cancers 2022, 14, 321. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020321

AMA Style

Kwok M, Agathanggelou A, Davies N, Stankovic T. Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681. Cancers. 2022; 14(2):321. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020321

Chicago/Turabian Style

Kwok, Marwan, Angelo Agathanggelou, Nicholas Davies, and Tatjana Stankovic. 2022. "Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681" Cancers 14, no. 2: 321. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14020321

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop